Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622479 · ClinicalTrials.gov registry record · Phase 1
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
A Phase 1 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00622479 is a Phase 1 study that was terminated before completion, run by Bayer. The registered enrollment target is 12 participants.
The verdict
NCT00622479, a Phase 1 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to: 1. To elucidate the mechanism involved in the sorafenib-induced hypophosphatemia and possible early effect of hypophosphatemia on bone mineral density 2. A secondary objective to assess the effect sorafenib treatment on evaluate left ventricular function (LVEF) and Beta-type natriuretic peptide in plasma.
Interventions
- DRUG Sorafenib (Nexavar, BAY43-9006)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622479
The ClinicalTrials.gov registry entry for NCT00622479 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sorafenib (Nexavar, BAY43-9006) is the first listed.
NCT00622479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00622479 about?
NCT00622479 is a clinical study titled "Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.". The purpose of this study is to: 1. To elucidate the mechanism involved in the sorafenib-induced hypophosphatemia and possible early effect of hypophosphatemia on bone mineral density 2. A secondary objective to assess the effect sorafenib treatment on evaluate left ventricular function (LVEF) and ...
What is the current status of trial NCT00622479?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00622479?
The interventions under investigation include: Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00622479?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.